Abstract:: The limited efficacy of the two malaria vaccines, RTS,S/AS01 and R21/Matrix M, which were recently approved vaccines by the World Health Organization, highlights the need for alternative vaccine candidate genes beyond these pre-erythrocytic-based vaccines. Plasmodium falciparum Reticulocyte Binding Protein Homologue 5 ( ) is a potential malaria vaccine candidate, given its limited polymorphism compared to other parasites blood stage antigens. This study evaluated the genetic diversity of the gene among parasites from regions with varying malaria transmission intensities in Mainland Tanzania, to generate baseline data for this potential malaria vaccine candidate. : This study utilized secondary data of 697 whole-genome sequences from Mainland Tanzania, which were generated by the MalariaGEN Community Network. The samples which were sequenced to generate the data were collected between 2010 and 2015 from five districts within five regions of Mainland Tanzania, with varying endemicities (Morogoro urban district in Morogoro region, Muheza district in Tanga region, Kigoma-Ujiji district in Kigoma region, Muleba district in Kagera region, and Nachingwea district in Lindi region). The genetic diversity of the gene was assessed using different genetic metrics, including Wright′s fixation index (F ), Wright′s inbreeding coefficient (Fws), Principal Component analysis (PCA), nucleotide diversity (π), haplotype network, haplotype diversity (Hd), Tajma′s D, and Linkage disequilibrium (LD). . Of the sequences used in this study (n=697), 84.5% (n = 589/697) passed quality control and 313 (53.1%) were monoclonal, and these monoclonal sequences were used for haplotype diversity and haplotype network analysis. High within-host diversity (Fws <0.95) was reported in Kigoma-Ujiji (60.7%), Morogoro urban (53.1%), and Nachingwea (50.8%), while Muleba (53.9%) and Muheza (61.6%) had low within host diversity (Fws≥ 0.95). PCA did not show any population structure across the five districts and the mean F value among the study populations was 0.015. Low nucleotide diversity values were observed across the study sites with the mean nucleotide diversity of 0.00056. A total of 27 haplotypes were observed among the 313 monoclonal samples. The Pf3D7 was detected as Hap_1, and it was detected in 16/313 (5.1%) sequences, and these sample sequences were from Muheza (62.5%, n=10/16), Kigoma-Ujiji (18.8%, n=3/16), and Muleba (18.8%, n=3/16). Negative Tajima′s D values were observed among the parasite populations in all the study sites. . In this study, we observed low levels of polymorphism in the gene, as it exhibited low nucleotide and haplotype diversity, a lack of population structure and negative Tajima′s D values as signatures of purifying selection. This study provides an essential framework of the diversity of the gene to be considered in development of the next generation malaria vaccines. Robust and intensive studies of this and other candidate genes are required for characterization of the parasites from areas with varying endemicity, and are crucial to support the prioritization of the gene for potential inclusion in a broadly cross-protective malaria vaccine.

The selective pressure induced by malaria vaccines on Plasmodium falciparum

Autoantibodies Inhibit Plasmodium Falciparum Growth and Are Associated with Protection from Clinical Malaria

Dendritic Cell Responses to Plasmodium Falciparum in a Malaria-Endemic Setting

Diversity and selection analyses identify transmission-blocking antigens as the optimal vaccine candidates in Plasmodium falciparum

Genetic polymorphism and evidence of signatures of selection in the Plasmodium falciparum circumsporozoite protein gene in Tanzanian regions with different malaria endemicity

Malaria vaccines: a new era of prevention and control

Performance characteristics and potential public health impact of improved pre-erythrocytic malaria vaccines targeting childhood burden

Blood-stage malaria vaccines — recent progress and future challenges

Sporozoite immunization: Innovative Translational Science to Support the Fight against malaria

Challenges in malaria control in sub-Saharan Africa: the vaccine perspective

Plasmodium falciparum pre-erythrocytic stage vaccine development

Genetic Diversity of the Plasmodium falciparum Reticulocyte Binding protein Homologue-5 which is a potential Malaria Vaccine Candidate: Baseline data from areas of varying malaria endemicity in Mainland Tanzania.

Vaccines and monoclonal antibodies: new tools for malaria control

Malaria vaccination: hurdles to reach high-risk children

Whole-sporozoite malaria vaccines: where we are, where we are going

Malaria vaccines in the eradication era: current status and future perspectives

Recent advances on vaccines against malaria: A review

Designer Parasites: Genetically Engineered Plasmodium as Vaccines To Prevent Malaria Infection

Targeting Plasmodium Life Cycle with Novel Parasite Ligands as Vaccine Antigens

Synergizing Health Strategies: Exploring the Interplay of Treatment and Vaccination in an Age-Structured Malaria Model